

SHORT TITLE: ARRY 3

RESEARCH PROTOCOL TITLE: A Phase 3, Multinational Randomized, Placebo-controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to Lamin A/C Gene Mutation

PRINCIPAL INVESTIGATOR: John Moses, MD

RESEARCH SPONSOR: Array BioPharma Inc.

Clinical Trials.Gov Listing at:

<https://clinicaltrials.gov/ct2/show/NCT03439514?term=array+797&rank=1>

STUDY PURPOSE

The main purpose of the research study is to evaluate the efficacy, safety and the effect of ARRY-371797 (the experimental drug) on the ability to walk over a 6-minute period (as measured by the 6-minute walk test) compared to placebo.

STUDY PROCEDURES

This study may last for several years. The visits may include blood tests, physical exams EKG's, vital signs, 6 minute walk tests, and questionnaires. The visits are every four to twelve weeks.

ELIGIBILITY CRITERIA FOR SUBJECTS

Age 18 years or older
Have symptomatic Cardiomyopathy (a disease that effects heart muscle)
Have a mutation of the LMNA gene
Have an internal cardiac defibrillator

SUBJECT PAYMENT

Participants will be compensated \$50 for each completed clinic study visit.

RESEARCH LOCATION AND CONTACT PERSON

Lynn Skatrud, RN, CCRC
UnityPoint Health-Meriter-Heart & Vascular Institute
2601 West Beltline Hwy.
Suite 200
Madison, WI 53713

PHONE: 608-417-2168